Nigel McCracken
Chief Tech/Sci/R&D Officer en BERGENBIO ASA .
Perfil
Nigel McCracken is currently the Chief Scientific Officer at BerGenBio ASA and the Chief Operating Officer at Virax Biolabs Group Ltd.
He previously worked as the Executive Director & VP-Translational Medicine at Debiopharm International SA from 2014 to 2019.
He also held a position as COO and Senior VP-Discovery & Early Development at NuCana Plc.
Dr. McCracken received his undergraduate degree from the University of Strathclyde and his graduate degree from King's College London.
Cargos activos de Nigel McCracken
| Empresas | Cargo | Inicio |
|---|---|---|
| BERGENBIO ASA | Chief Tech/Sci/R&D Officer | 01/01/2021 |
| VIRAX BIOLABS GROUP LIMITED | Chief Operating Officer | 01/09/2023 |
Antiguos cargos conocidos de Nigel McCracken.
| Empresas | Cargo | Fin |
|---|---|---|
Debiopharm International SA
 Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | Director/Board Member | 01/04/2019 |
| NUCANA PLC | Chief Operating Officer | - |
Formación de Nigel McCracken.
| University of Strathclyde | Undergraduate Degree |
| King's College London | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| BERGENBIO ASA | Health Technology |
| NUCANA PLC | Health Technology |
| VIRAX BIOLABS GROUP LIMITED | Finance |
| Empresas privadas | 1 |
|---|---|
Debiopharm International SA
Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | Health Technology |
- Bolsa de valores
- Insiders
- Nigel McCracken
